Therapy for myeloproliferative neoplasms: When, which agent, and how?

Blood

Volumn 124, Issue 24, 2014, Pages 3529-3537

  Geyer, Holly L ^a   Mesa, Ruben A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; JANUS KINASE; JANUS KINASE 2 INHIBITOR; RUXOLITINIB; 11-(2-PYRROLIDIN-1-YLETHOXY)-14,19-DIOXA-5,7,26-TRIAZATETRACYCLO(19.3.1.1(2,6).1(8,12))HEPTACOSA-1(25),2(26),3,5,8,10,12(27),16,21,23-DECAENE; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; BRIDGED COMPOUND; JAK2 PROTEIN, HUMAN; JANUS KINASE 2; N-(CYANOMETHYL)-4-(2-((4-(4-MORPHOLINYL)PHENYL)AMINO)-4-PYRIMIDINYL)BENZAMIDE; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE; TUMOR PROTEIN;

ABDOMINAL DISCOMFORT; ALGORITHM; ALLOGENEIC STEM CELL TRANSPLANTATION; BONE PAIN; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER SURVIVAL; CANCER THERAPY; CYTOREDUCTIVE SURGERY; DRUG EFFICACY; EPIGENETICS; FATIGUE; FEVER; GENE MUTATION; GENETIC REGULATION; GRAFT VERSUS HOST REACTION; HIGH RISK PATIENT; HUMAN; LIFE EXPECTANCY; MYELOPROLIFERATIVE NEOPLASM; NIGHT SWEAT; OVERALL SURVIVAL; PATIENT ASSESSMENT; PHLEBOTOMY; PHYSICAL INACTIVITY; POLYCYTHEMIA VERA; PRACTICE GUIDELINE; PRURITUS; QUALITY OF LIFE; REVIEW; SATIETY; SCORING SYSTEM; THROMBOCYTE COUNT; THROMBOCYTHEMIA; WEIGHT REDUCTION; ANTAGONISTS AND INHIBITORS; DRUG DELIVERY SYSTEM; ENZYMOLOGY; HEMATOLOGIC NEOPLASMS; MYELOPROLIFERATIVE DISORDERS; PHASE 3 CLINICAL TRIAL (TOPIC);

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZAMIDES; BRIDGED COMPOUNDS; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG DELIVERY SYSTEMS; HEMATOLOGIC NEOPLASMS; HUMANS; JANUS KINASE 2; MYELOPROLIFERATIVE DISORDERS; NEOPLASM PROTEINS; PYRAZOLES; PYRIMIDINES; QUALITY OF LIFE;

EID: 84916201113     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-05-577635     Document Type: Review

References (75)

1. Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia. 2008;22(1):14-22.
2. Gangat N, Caramazza D, Vaidya R, et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol. 2011;29(4):392-397.
3. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7(4):387-397.
4. Scott LM, Tong W, Levine RL, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med. 2007;356(5):459-468.
5. Pardanani A, Lasho TL, Finke C, Hanson CA, Tefferi A. Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera. Leukemia. 2007;21(9):1960-1963.
6. Martinez-Aviles L, Besses C, Alvarez-Larran A, Cervantes F, Hernandez-Boluda JC, Bellosillo B. JAK2 exon 12 mutations in polycythemia vera or idiopathic erythrocytosis. Haematologica. 2007;92(12):1717-1718.
7. Vannucchi AM, Antonioli E, Guglielmelli P, et al. Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia. Blood. 2008;112(3):844-847.
8. Pardanani AD, Levine RL, Lasho T, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood. 2006;108(10):3472-3476.
9. Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia. 2010;24(6):1128-1138.
10. Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013;369(25):2391-2405.
11. Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369(25):2379-2390.
12. Guglielmelli P, Rotunno G, Mannarelli C, et al. CALR mutation is a strong independent favorable prognostic variable in primary myelofibrosis. Paper presented at the European Hematology Association Annual Meeting, June 12-15, 2014, Milan, Italy.
13. Tefferi A, Guglielmelli P, Lasho TL, et al. CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients. Leukemia. 2014;28(7):1494-1500.
14. Tefferi A, Lasho TL, Finke C, et al. Type 1 vs type 2 calreticulin mutations in primary myelofibrosis: differences in phenotype and prognostic impact. Leukemia. 2014;28(7):1568-1570.
15. Rumi E, Pietra D, Ferretti V, et al. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood. 2014; 123(10):1544-1551.
16. Krähling T, Torda A, Bors A, et al. Clinical charecteristics in myeloproliferative neoplasm with calreticulin mutations.Paper presented at the European Hematology Association Annual Meeting, June 12-15, 2014, Milan, Italy.
17. Verger E, Dosquet C, Andreoli A, Schlageter M-H, Chomienne C, Kiladjian J-J. Clinical and molecular response to inerferon alpha therapy in essential thrombocythemia patients with CALR mutations.Paper presented at the European Hematology Association Annual Meeting, June 12-15, 2014, Milan, Italy.
18. Panagiota V, Thol F, Markus B, et al. Outcome of JAK2/MPL/CALR triple negative patients with myelofibrosis after allogeneic stem cell transplantation.Paper presented at the European Hematology Association Annual Meeting, June 12-15, 2014, Milan, Italy.
19. Mesa RA, Niblack J, Wadleigh M, et al. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients. Cancer. 2007;109(1):68-76.
20. Scherber R, Dueck AC, Johansson P, et al. The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients. Blood. 2011;118(2):401-408.
21. Emanuel RM, Dueck AC, Geyer HL, et al. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol. 2012;30(33):4098-4103.
22. Emanuel R, Dueck AC, Geyer HL, et al. Myeloproliferative (MPN) symptom burden response thresholds: assessment of MPN-SAF TSS quartiles as potential markers of symptom response [abstract]. Blood (ASH Annual Meeting Abstracts). 2013;122(21):4067.
23. Tefferi A, Elliott M. Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F. Semin Thromb Hemost. 2007;33(4):313-320.
24. Passamonti F, Rumi E, Arcaini L, et al. Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients. Haematologica. 2008;93(11):1645-1651.
25. Tam CS, Nussenzveig RM, Popat U, et al. The natural history and treatment outcome of blast phase BCR-ABL-myeloproliferative neoplasms. Blood. 2008;112(5):1628-1637.
26. Passamonti F, Thiele J, Girodon F, et al. A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment. Blood. 2012;120(6):1197-1201.
27. Tefferi A, Rumi E, Finazzi G, et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia. 2013;27(9):1874-1881.
28. Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009;113(13):2895-2901.
29. Passamonti F, Cervantes F, Vannucchi AM, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood. 2010;115(9):1703-1708.
30. Geyer HL, Emanuel RM, Dueck AC, et al. Distinct clustering of symptomatic burden amongst myeloproliferative neoplasm patients: retrospective assessment in 1470 patients. Blood. 2014;123(24):3803-3810.
31. Barbui T, Barosi G, Birgegard G, et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol. 2011;29(6):761-770.
32. Landolfi R, Marchioli R, Kutti J, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med. 2004;350(2):114-124.
33. Marchioli R, Finazzi G, Specchia G, et al. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med. 2013;368(1):22-33.
34. Harrison CN, Campbell PJ, Buck G, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005;353(1):33-45.
35. Gisslinger H, Gotic M, Holowiecki J, et al. Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial. Blood. 2013;121(10):1720-1728.
36. Quintas-Cardama A, Abdel-Wahab O, Manshouri T, et al. Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon alpha-2a. Blood. 2013;122(6):893-901.
37. Kiladjian JJ, Chevret S, Dosquet C, Chomienne C, Rain JD. Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980. J Clin Oncol. 2011;29(29):3907-3913.
38. Mesa RA, Steensma DP, Pardanani A, et al. A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. Blood. 2003;101(7):2534-2541.
39. Mesa RA, Yao X, Cripe LD, et al. Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903. Blood. 2010;116(22):4436-4438.
40. Tefferi A, Passamonti F, Barbui T, et al. Phase 3 study of pomalidomide in myeloproliferative neoplasm (MPN)-associated myelofibrosis with RBC-transfusion-dependence [abstract]. Blood (ASH Annual Meeting Abstracts). 2013;122(21):394.
41. Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366(9):787-798.
42. Mesa RA, Nagorney DS, Schwager S, Allred J, Tefferi A. Palliative goals, patient selection, and perioperative platelet management: outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic. Cancer. 2006;107(2):361-370.
43. Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366(9):799-807.
44. Harrison CN, Niederwieser D, Vannucchi A, et al. Results from a 3.5 year update of COMFORT-II, a phase 3 study comparing ruxolitinib (Rux) with best available therapy (BAT) for the treatment of myelofibrosis.Paper presented at the European Hematology Association Annual Meeting, June 12-15, 2014, Milan, Italy.
45. Mesa RA, Verstovsek S, Gupta V, et al. Improvement in weight and total cholesterol and their association with survival in ruxolitinib-treated patients with myelofibrosis from COMFORT-I [abstract]. Blood (ASH Annual Meeting Abstracts). 2012;120(21):1733.
46. Harrison CN, Clark RE, Chacko J, et al. Response to ruxolitinib in patients with intermediate-1, intermediate-2 and high-risk myelofibrosis:interim results of the UK Robust Trial [abstract]. Blood (ASH Annual Meeting Abstracts). 2013;122(21):2826.
47. Verstovsek S, Passamonti F, Rambaldi A, et al. A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea. Cancer. 2014;120(4):513-520.
48. Vannucchi A, Kiladjian J-J, Griesshammer M, et al. Results of a prospective, randomized, open-label Phase III study of ruxolitinib in polycythemia vera patients resistant to or intolerant of hydroxyurea: the RESPONSE trial.Paper presented at the European Hematology Association Annual Meeting, June 12-15, 2014, Milan, Italy.
49. Pardanani A, Laborde RR, Lasho TL, et al. Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis. Leukemia. 2013;27(6):1322-1327.
50. Verstovsek S, Dean JP, Cernohous P, et al. Pacritinib, a dual JAK2/FLT3 inhibitor: an integrated efficacy and safety analysis of phase II trial data in patients with primary and secondary myelofibrosis (MF) and platelet counts ≤ 100,000/μl [abstract]. Blood (ASH Annual Meeting Abstracts). 2013;122(21):395.
51. Pardanini A, Harrison CN, Cortes JE, et al. Results of a randomized, double-blind, placebo-controlled phase III study (JAKARTA) of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis (MF) [abstract]. Blood (ASH Annual Meeting Abstracts). 2013;122(21):393.
52. Cantley LC. The phosphoinositide 3-kinase pathway. Science. 2002;296(5573):1655-1657.
53. Burchert A, Wang Y, Cai D, et al. Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development. Leukemia. 2005;19(10):1774-1782.
54. Choong ML, Pecquet C, Pendharkar V, et al. Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors. J Cell Mol Med. 2013;17(11):1397-1409.
55. Loewith R, Jacinto E, Wullschleger S, et al. Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol Cell. 2002;10(3):457-468.
56. Guglielmelli P, Barosi G, Rambaldi A, et al. Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis. Blood. 2011;118(8):2069-2076.
57. Amaru Calzada A, Todoerti K, Donadoni L, et al. The HDAC inhibitor Givinostat modulates the hematopoietic transcription factors NFE2 and C-MYB in JAK2(V617F) myeloproliferative neoplasm cells. Exp Hematol. 2012;40(8):634-645 e610.
58. Cooper CL, Hardy RR, Reth M, Desiderio S. Non-cell-autonomous hedgehog signaling promotes murine B lymphopoiesis from hematopoietic progenitors. Blood. 2012;119(23):5438-5448.
59. Verstovsek S, Mesa R, Foltz L, et al. Phase 2 trial of PRM-151, an anti-fibrotic agent, in patients with myelofibrosis: stage 1 results.Paper presented at the European Hematology Association Annual Meeting, June 12-15, 2014, Milan, Italy.
60. Baerlocher G, Leibundgut E, Ayran C, et al. Imetelstat rapidly induces and maintains substantial hematologica and molecular responses in patients with essential thrombocythemia (ET) who are refractory or intolerant to prior therapy: preliminary phase II results [abstract]. Blood (ASH Annual Meeting Abstracts). 2012;120(21):179.
61. Tefferi A, Begna K, Laborde R, et al. Imetelstat, a telomerase inhibitor, induces morphologica and molecular remissions in myelofibrosis and recersal of bone marrow fibrosis [abstract]. Blood (ASH Annual Meeting Abstracts). 2012;120(21):662.
62. Robin M, Francois S, Huynh A, et al. Ruxolitinib before allogeneic hematopoietic stem cell transplantation (HSCT) in patients with myelofibrosis: a preliminary descriptive report of the JAK ALLO study, a phase II trial sponsored by Goelams-FIM in collaboration with the SFGMTC [abstract]. Blood (ASH Annual Meeting Abstracts). 2013;122(21):306.
63. Kroger N, Alchalby H, Ditschkowski M, et al. Ruxolitinib as pretreatment before allogeneic stem cell transplantation for myelofibrosis [abstract]. Blood (ASH Annual Meeting Abstracts). 2013;122(21):392.
64. Cherington C, Slack JL, Leis J, et al. Allogeneic stem cell transplantation for myeloproliferative neoplasm in blast phase. Leuk Res. 2012;36(9):1147-1151.
65. Barbui T, Carobbio A, Cervantes F, et al. Thrombosis in primary myelofibrosis: incidence and risk factors. Blood. 2010;115(4):778-782.
66. Elliott MA, Pardanani A, Lasho TL, Schwager SM, Tefferi A. Thrombosis in myelofibrosis: prior thrombosis is the only predictive factor and most venous events are provoked. Haematologica. 2010;95(10):1788-1791.
67. Cortelazzo S, Viero P, Finazzi G, D'Emilio A, Rodeghiero F, Barbui T. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J Clin Oncol. 1990;8(3):556-562.
68. Marchioli R, Finazzi G, Landolfi R, et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol. 2005;23(10):2224-2232.
69. Passamonti F, Rumi E, Pungolino E, et al. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med. 2004;117(10):755-761.
70. Barbui T, Thiele J, Passamonti F, et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol. 2011;29(23):3179-3184.
71. Passamonti F, Rumi E, Elena C, et al. Incidence of leukaemia in patients with primary myelofibrosis and RBC-transfusion-dependence. Br J Haematol. 2010;150(6):719-721.
72. Bonicelli G, Abdulkarim K, Mounier M, et al. Leucocytosis and thrombosis at diagnosis are associated with poor survival in polycythaemia vera: a population-based study of 327 patients. Br J Haematol. 2013;160(2):251-254.
73. Sever M, Quintas-Cardama A, Pierce S, Zhou L, Kantarjian H, Verstovsek S. Significance of cytogenetic abnormalities in patients with polycythemia vera. Leuk Lymphoma. 2013;54(12):2667-2670.
74. Huang J, Li CY, Mesa RA, et al. Risk factors for leukemic transformation in patients with primary myelofibrosis. Cancer. 2008;112(12):2726-2732.
75. Mesa RA, Li CY, Ketterling RP, Schroeder GS, Knudson RA, Tefferi A. Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. Blood. 2005;105(3):973-977.